Velacur: Providing patients with early detection of liver disease

Oct 25, 2022
Sonic Incytes' Velacur logo. A purple to light blue gradient made up of polkadots.

One in five Canadians have nonalcoholic fatty liver disease (NAFLD), which can lead to liver cirrhosis and cancer. While there are no drugs on the market, NAFLD can often be reversed with lifestyle changes, such as diet and exercise. Sadly, given that there are often no initial symptoms, patients tend to go undiagnosed until they arrive in the emergency room presenting with cirrhosis.

Sonic Incytes is helping to diagnose liver disease early, so that patients can take necessary steps to manage this condition.

Based in Vancouver, BC, Sonic Incytes has introduced an innovative tool to the market called Velacur™, which aids in the clinical management of patients with liver disease.

Sonic Incytes’ proprietary technology was invented by University of British Columbia professors Tim Salcudean and Robert Rohling. Velacur™ uses an external activation board similar to MRI elastography to generate steady state shear waves through the liver that are then measured via a typical ultrasound. Based on the relative mechanical properties of the different tissues, liver stiffness and fat can be easily and quickly quantified.

As part of their Pilot Fund project with INOVAIT, Sonic Incytes has been developing AI software to improve the ease of use of Velacur for medical professionals who may not be ultrasound specialists. Sonic Incytes hopes to ultimately achieve adoption in primary care, where liver assessment could, over time, become the next vital sign; similar to the way that blood pressure and heart rate is monitored at a visit to the doctor’s office.

Velacur could be transformational by aiding in the detection of liver disease well before the condition progresses to an advanced stage, giving patients the opportunity to change lifestyle habits before it’s too late.

INOVAIT’s Pilot Fund provides support for commercialization-focused R&D projects involving the integration of AI into image-guided therapy technologies. For more information on how to apply, visit inovait.ca/funding. To learn more about Velacur and Sonic Incytes, visit sonicincytes.com.

Partagez ceci sur les réseaux sociaux

En savoir plus sur nous

Du risque à l’hyperprécision : Comment ViTAA Medical tire profit de l’imagerie et de l’IA pour redéfinir le traitement de l’anévrisme aortique

Du risque à l’hyperprécision : Comment ViTAA Medical tire profit de l’imagerie et de l’IA pour redéfinir le traitement de l’anévrisme aortique

Using AI-assisted 3D modelling, ViTAA Medical is determined to bring aneurysm management into the 21st century. For the last 15 years, Dr. Elena Di Martino, a biomedical engineer and Dr. Randy Moore, a vascular surgeon (both teach at the University of Calgary), have been perfecting technology that uses computer algorithms to analyze information gathered on a CT scan to create 3D models of aneurysms that encode the actual mechanical properties of the vessel’s wall.